![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Weight Loss Drugs Could Bankrupt US Healthcare, Senate Report Warns
Weight Loss Drugs Could Bankrupt US Healthcare, Senate Report Warns
Citing company “greed,” Sen. Bernie Sanders (I-Vt.) has again blasted Danish pharma Novo Nordisk for the prices of Wegovy and Ozempic, releasing a Senate committee report claiming the popular weight loss and diabetes drugs could bankrupt the US healthcare system.
The report comes less than two months after Sanders — Chairman of the Senate Health, Education, Labor and Pensions (HELP) Committee — ripped the company after a JAMA Network Open article cited that Medicare spending on Ozempic alone reached $4.6 billion in 2022.
The report from the HELP Committee under Sanders’ chairmanship continues its track record of comparing US drug prices to those in other countries. A February Committee hearing grilled Merck CEO Robert Davis, who blamed rebates big pharma must offer to pharmacy benefit managers, a charge rebuffed by the Committee.
To read the whole story, click here.
Related Topics
Upcoming Events
-
18Jul
-
21Oct